Clinical Manager

dr. vladimir liska, phd, msc

**** ****** ****, *.*. Box 3-215-***-****

Skippack, PA 19474-0003 abhkd3@r.postjobfree.com

Summary

Infectious diseases / Vaccines / Clinical & Regulatory / Pharm R&D /

Vaccine & Virology Basic Research

Highly motivated professional with over two decades of international

experience in the field of infectious diseases / virology / vaccines

including experience in vaccine clinical research, vaccine pharmaceutical

research and development (PR&D), vaccine manufacturing and vaccine/virology

basic research. Pre-clinical experience includes development of vaccine

formulations, vaccine technology scale-up and transfer, process validation

of vaccine manufacturing processes, and participation in cross-functional/

international teams focused on life cycle management of vaccines/biologics.

Clinical experience in clinical monitoring of phase III clinical trials.

Clinical assay-related experience in organizing/coordinating activities of

clinical teams, basic research and clinical laboratories for various

vaccine-related clinical projects. Managerial experience in chairing/co-

chairing cross-functional teams on various vaccine-oriented projects.

Recognized as a proactive, results-oriented team player with strong

leadership, communication and organizational skills.

Professional Experience

Merck & Co., Inc, Merck Research Laboratories, West Point, PA, USA 1999-

2010

Clinical Research Liaison / Clinical Monitor, Vaccine Clinical Research

(2005-2010)

. Clinical science liaison for clinical assay-related issues on vaccine-

related projects.

. Lead clinical monitor on RECOMBIVAX HB , modified process phase III

studies.

. Facilitated communication between clinical teams, basic research and

clinical laboratories on vaccine-related projects.

. Supported basic research, validation and maintenance of clinical assays

used in vaccine-related clinical programs.

Group Leader / Manager, Vaccine & Biologics R&D (1999-2005)

. Pre-clinical PR&D representative responsible for life cycle management of

M-M-R II and ProQuad vaccines.

. Responsible for the technology transfer and the process validation of

ProQuad (Frozen & Refrigerated) vaccines.

. Supervised development of new formulations for live viral vaccines.

. Supervised an early phase development of recombinant protein-based anti-

bacterial vaccines.

. Supervised replacement of excipients of animal and human origin in

vaccine formulations.

Harvard University, Boston, MA, USA 1994-1999

Dana-Farber Cancer Institute, Boston, MA, USA

Instructor in Medicine

. Studied pathogenesis of live-attenuated simian immunodeficiency virus

(SIV) vaccine in rhesus monkey model.

. Demonstrated infection and development of AIDS in adult macaques after

oral exposure to cell-free SIV.

. Studied active and passive immunoprophylactic strategies to prevent AIDS

virus infection in rhesus monkey model.

National Institute of health, National Cancer Institute, Frederick, MD, USA

1993-1994

Post-Doctoral Fellow

. Studied morphology and subunit structure of human and animal AIDS viruses

(HIV/SIV).

french National Institute of health and medical research (INSERM),

Strasbourg, France 1991-1993

Post-Doctoral Fellow

. Studied roles of viral accessory proteins during the life cycle of SIV.

Institute of Sera and Vaccines (SEVAC), Prague, Czechoslovakia

1985-1991

Research Scientist (1987-1991)

. Developed a commercial diagnostic ELISA assay for detection of HIV-1

antibodies from human plasma.

Research Scientist (1985-1987)

. Supervised the manufacturing and safety testing of live-attenuated

measles vaccine.

Education

. PhD (Doctor of Philosophy / Medical Microbiology, 2008), University of

Defense, Hradec Kralove, Czech Republic

. RNDr (Doctor of Natural Sciences / Microbiology, 1985), Charles

University, Prague, Czechoslovakia

. MSc (Mater of Science / Education/Biology/Chemistry, 1985), Charles

University, Prague, Czechoslovakia

Languages

. Czech (Expert)

. English (Expert)

. Slovak (Expert)

. Russian (Expert)

Publications

Original Papers in Peer-Reviewed Journals:

1. Vesikari T, Martin JC, Liss CL, Liska V, Sch del FP, Bhuyan PK. Safety

and Immunogenicity of a Modified Process Hepatitis B Vaccine in Healthy

Infants. Pediatr Infect Dis J; In press

2. Liska V, Bigert SA, Bennett PS, Olsen D, Chang R, Burke CJ. Evaluation

of a recombinant human gelatin as a substitute for a hydrolyzed porcine

gelatin in a refrigerator-stable Oka/Merck live varicella vaccine. J

Immune Based Ther Vaccines 2007; 5: 4

3. Buckley KA, Li PL, Khimani A, Hofmann-Lehmann R, Liska V, Anderson D,

McClure HM, Ruprecht RM. Convergent evolution of SIV env after

independent inoculation of rhesus macaques with infectious proviral DNA

Virology 2003;312: 470 - 480 (Cited 1 time)

4. Pion M, Sanchez G, Liska V, Bettendroffer L, Candotti D, Chenine AG,

Gondois-Rey F, Tamalet C, Vigne R, Ruprecht RM, Agut H, the French ALT

Study Group, Hirsch I. Truncated forms of human and simian

immunodeficiency virus in infected individuals and rhesus macaques are

unique or rare quasispecies. Virology 2003; 311: 157 - 168 (Cited 1 time)

5. Rasmussen RA, Hofmann-Lehmann R, Montefiori DC, Li P, Liska V, Vlasak J,

Baba TW, Schmitz JE, Kuroda MJ, Robinson HL, McClure HM, Lu S, Hu S,

Rizvi TA, Ruprecht RM. DNA prime/protein boost vaccine strategy in

neonatal macaques against simian human immunodeficiency virus. J Med

Primatol 2002; 31: 1-21 (Cited 9 times)

6. Von Gegerfelt AS, Liska V, Li PL, McClure HM, Horie K, Nappi F,

Montefiori DC, Pavlakis GN, Marthas ML, Ruprecht RM, Felber BK.Rev-

Independent simian immunodeficiency virus strains are nonpathogenic in

neonatal macaques. J Virol 2002; 76(1): 96-104 (Cited 4 times)

7. Pion M, Liska V, Chenine A-L, Hofmann-Lehmann R, Vlasak J, Gondois-Rey

F, Ruprecht RM, Hirsch I. Extensively deleted simian immunodeficiency

virus (SIV) DNA in macaques inoculated with supercoiled plasmid DNA

encoding full-length SIVmac239. Virol 2001; 289: 103-113 (Cited 3 times)

8. Hofmann-Lehmann R, Rasmussen RA, Vlasak J, Smith BA, Baba TW, Liska V,

Montefiori DC, McClure HM, Anderson DC, Bernacky BJ, Rizvi TA, Schmidt R,

Hill LR, Keeling ME, Katinger H, Stiegler G, Posner MR, Cavacini LA, Chou

TC, Ruprecht RM. Passive immunization against oral AIDS virus

transmission: Asn approach to prevent mother-to-infant HIV-1

transmission? J Med Primatol 2001; 30: 190-196 (Cited 6 times)

9. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, Smith BA, Baba TW, Liska V,

Montefiori DC, McClure, Anderson DC, Bernacky BJ, Rizvi TA, Schmidt R,

Hill LR, Keeling ME, Katinger H, Stiegler G, Cavacini LA, Posner MR, Chou

TC, Andersen J, Ruprecht RM. Postnatal passive immunization of neonatal

macaques with a triple combination of human monoclonal antibodies against

oral simian-human immunodeficiency virus challenge. J Virol 2001; 75

(16): 7470-7480 (Cited 35 times)

10. Ruprecht RM, Hofmann-Lehmann R, Smith-Franklin BA, Rasmussen RA, Liska

V, Vlasak J, Xu W, Baba TW, Chenine A-L, Cavacini LA, Posner MR, Katinger

H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME,

Montefiori DC. Protection of neonatal macaques against experimental SHIV

infection by human neutralizing monoclonal antibodies. Transfus Clin Biol

2001; 8: 350-358 (Cited 5 times)

11. Liska V, Hofmann-Lehmann R, Ruprecht RM. Infectivity of Lentiviral DNA

in Animals. Dev Biol Stand 2001; 106: 291-298

12. Hofmann-Lehmann R, Swenerton RK, Liska V, Leutenegger CM, Lutz H,

McClure HM, Ruprecht RM. Sensitive and robust one-tube real-time reverse

transcriptase-polymerase chain reaction to quantify SIV RNA load:

Comparison of one- versus two-enzyme systems. AIDS Res Human Retroviruses

2000; 16 (13): 1247 - 1257 (Cited 37 times)

13. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S,

Cavacini LA, Posner M, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA,

Schmidt R, Hill LR, Keeling ME, Lu Y, Wright JE, Ruprecht RM. Human

neutralizing monoclonal antibodies of the IgG1 subtype protect against

simian-human immunodeficiency virus infection. Nat Med 2000; 6 (2):200-

206 (Cited 238 times)

14. Von Gegerfelt A, Liska V, Ray NB, McClure HM, Ruprecht RM, Felber BK.

Persistent infection of rhesus macaques by the Rev-independent Nef SIVmac239: Replication kinetics and genomic stability. J Virol 1999; 73

(7): 6159 - 6165 (Cited 8 times)

15. Liska V, Ruprecht RM. Isolation of high-molecular-weight genomic DNA

from biohazardous mammalian tissues. Biotechniques 1999; 26: 62-64 (Cited

5 times)

16. Liska V, Khimani A, Hofmann-Lehmann R, Fink A, Vlasak J, Ruprecht RM.

Viremia and AIDS in rhesus macaques after intramuscular inoculation of

plasmid DNA encoding full-length SIVmac239. AIDS Res Hum Retroviruses

1999; 15 (5): 445 - 450 (Cited 19 times)

17. Baba TW, Liska V, Li A, Khimani A, Dailey JP, Pennick D, Greene MF,

McClure HM, Ruprecht RM. Live attenuated, multiply deleted simian

immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med

1999; 5 (2): 194 - 203 (Cited 144 times)

18. Ruprecht RM, Baba TW, Liska V, Ray N, Martin LN, Murphey-Corb M, Rizvi

T, Bernacky BJ, Keeling M, Andersen J. Oral transmission of primate

lentiviruses. J Inf Diseases 1999: 179 (Suppl. 3): S408-12 (Cited 14

times)

19. Ruprecht RM, Baba TW, Liska V, Ayehunie S, Andersen J, Montefiori D,

Trichel A, Murphey-Corb M, Martin LN, Rizvi T, Bernacky BJ, Keeling M.

Oral SIV, SHIV and HIV-1 infection. AIDS Res Hum Retroviruses 1998, 14

(Suppl. 1): S97 - 103 (Cited 14 times)

20. Liska V, Fultz PN, Su L, Ruprecht RM. Detection of simian T-cell

leukemia virus type 1 infection in seronegative macaques. AIDS Res Hum

Retroviruses 1997, 13 (13): 1147 - 1153 (Cited 16 times)

21. Liska V, Lerche NW, Ruprecht RM. Simultaneous detection of simian

retrovirus type D serotypes 1, 2 and 3 by polymerase chain reaction. AIDS

Res Hum Retroviruses 1997, 13 (5): 433 - 437 (Cited 14 times)

22. Baba TW, Trichel AM, Li A, Liska V, Martin LN, Murphey-Corb M, Ruprecht

RM. Infection and AIDS in adult macaques after atraumatic oral exposure

to cell-free SIV. Science 1996, 272: 1486 - 1489 (Cited 80 times)

23. Ruprecht RM, Baba WT, Liska V. Attenuated HIV vaccine: Caveats. Science

1996, 271: 1790 - 1792 (Cited 14 times)

24. Ruprecht RM, Hu Y, Liska V, Rasmussen R, Sharma P. Correlates of immune

protection after vaccination with attenuated live Murine leukemia virus.

AIDS Res Hum Retroviruses 1996, 12 (5): 375 - 377 (Cited 13 times)

25. Ruprecht RM, Baba TW, Liska V, Bronson R, Pennick D, Greene M.

"Attenuated" simian immunodeficiency virus in macaque neonates. AIDS Res

Hum Retroviruses 1996, 12 (5): 459 - 460 (Cited 13 times)

26. Ruprecht RM, Baba TW, Li A, Ayehunie S, Hu Y, Liska V, Rasmussen R,

Sharma PL. Live attenuated HIV as a vaccine for AIDS: pros and cons.

Semin Virol 1996, 7: 147-155 (Cited 7 times)

27. Ruprecht RM, Baba TW, Ayehunie S, Hu Y, Liska V, Li A, Montefiori DC,

Rasmussen R. SIV pathogenesis during ontogeny: the influence of host

factor. Dixi me Colloque des Cent Gardes 1995: 1-6 (Cited 0 times)

28. Baba TW, Liska V, Hu Y, Rasmussen R, Pennick D, Bronson R, Greene MF,

Ruprecht RM. Attenuated Retrovirus Vaccines and AIDS. Science 1995, 270:

1218 - 1221 (Cited 8 times)

29. Persidsky Y, Liska V, Huss T, Gendrault JL, Venet A, Muchmore E,

Traincard F, Kirn A, Aubertin AM. Presence of virion protein X of simian

immunodeficiency virus SIVmac in target cells in vivo. J Med Primatol

1995, 24: 35- 42

30. Liska V, Spehner D, Kieny MP, Mehtali M, Kirn A, Aubertin AM.

Localization of Virion Protein X from SIVmac and analysis of its

packaging requirements. J Gen Virol 1994, 75: 2955 - 2962 (Cited 12

times)

31. Liska V, Dyr JE, Suttnar J, Hirsch I, Vonka V. Production and simple

purification of a protein encoded by part of the gag gene of HIV-1 in the

E.Coli HB101+ expression system inducible by lactose and isopropyl-(-D-

thiogalactopyranoside. J Chromatogr B Biomed Appl. 1994, 656 (1): 127 -

133 (Cited 1 time)

32. Suttnar J, Dyr JE, Liska V, Vonka V. New ways of isolation of

recombinant proteins. Cas Lek Cesk 1992, 131 (24-25): 756-758

Book Chapters

1. Ruprecht RM, Liska V, Hofmann-Lehman R, Khimani AH, Rasmussen RA, Vlasak

J, McClure HM. Live attenuated AIDS vaccines: Where to go from here? In:

Brockmeyer NH, et al. (eds). HIV-Infekt: Epidemiologie, Pr vention,

Pathogenese, Diagnostik, Therapie, Psycho-Soziologie. Springer-Verlag:

Berlin Heidelberg New York. 2000; 15-22

2. Baba TW, Liska V, Ruprecht RM. HIV-1/SIV infection of the fetal and

neonatal nervous system. In: HE Gendelman, SA Lipton, L Epstein, S

Swindells: The Neurology of AIDS. Philadelphia: Chapman & Hall.1998, pp.

443-56

Contact this candidate